Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
101.40    -1.80 (-1.74%)
Bid:
101.40
Ask:
102.20
Spread: 0.80 (0.789%)
Market Cap: £166.24m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

17 May 2012 07:00

RNS Number : 5270D
Yule Catto & Co PLC
17 May 2012
Β 

ο»Ώ

Β 17 May 2012

Β 

Yule Catto & Co plc (the "Group")Β 

Β 

AGM & Interim Management Statement

Β 

At this morning's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter WoodΒ will make the following statement which also comprises the Group's interim management statement for the period 1 January 2012 to date.

Β 

Profitability for the period was substantially ahead of prior year* and inΒ line with the Board's expectations, in what has been a very challenging environment. The economic issues, particularly in Europe, have produced an environment of high raw material volatility and a general lack of business confidence.

Β 

In our Europe and North America segment, volumes in Q1 were 11% below what was a strong start to 2011, but 14% ahead of Q4 2011. Weakness was most evident in sales to the construction sector. Margin management has more than compensated for the lower volume levels, and together with the benefit of the planned synergies, the segment operating profit was substantially ahead of prior year.

Β 

In our Asia and ROW segment, the Construction and Coatings business unit showed good year on year improvement. However, inΒ Health and Protection, demand remained subdued. Asia and ROW volumes were down 1% on Q1 2011 and 11 % ahead of Q4 2011. Margins in Health and Protection in the first half of 2011 were reasonably strong and have not been maintained at these high levels. Consequently results overall for the segment were below prior year.

Β 

Synergies hit an annualised run rate of Β£20 million as at the end of Marchand remain on track for Β£25M at the end of Q1 next year. This represents a Β£15M full year synergy benefit to 2012 operating profits compared to prior year.

Β 

The Group's latex expansion in Malaysia remains on track for production in the fourth quarter. This expansion will allow us to keep pace with long term demand in the high growth nitrile latex market and allow additional growth through the sale of locally manufactured SBR.

Β 

Net debt at the end of April was Β£171M, slightly up on the year end position of Β£164M

Β 

The Board also notes the current weakness of the euro which has hit 1.25 against sterling in recent days, having averaged 1.20 over the first four months of 2012, and 1.15 through 2011. The Group made a little over half of its operating profit in the euro zone in 2011. The translation effect of a one cent movement in the euro equates to approximately Β£0.5M of operating profit.

Β 

The environment remains both challenging and volatile. Against this background, the Board is pleased with the Group's financial performance year to date, and its expectations for the performance of the Group over the remainder of the year remain unchanged.

Β 

Note: * The Group reported an underlying proforma PBT of Β£96.0M for full year 2011, which included an adjustment to reflect the first quarter's pre acquisition operating profit of PolymerLatex of Β£13.3M and an estimated interest cost of Β£2.1M. Comments on PBT, operating profit performance and volumes for the period under review compared to 2011 are based on this proforma basis.

Β 

- Ends -

Β 

ENQUIRIES:

Β 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

Β 

David Blackwood, Group Finance Director

Β 

Β 

Β 

Β 

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

Β 

John Olsen

Β 

Ian Payne

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSLFFELEVIRLIF
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.